Intuitive Surgical, Inc. (ISRG) fair value analysis
S&P 500 · Updated 2026-10-19
ISRG price how computed
Forward Fair Value verdict
UndervaluedISRG is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $423.96
- Sector
- Healthcare
- 12-month range
- $332.02–$592.85
- Market cap
- $150B
- From 52-week high
- -28.5%
- Shares outstanding
- 353M
- Rank in Healthcare by discount to fair value
- #20 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Intuitive Surgical, Inc. designs, manufactures, and markets robotic systems used in minimally invasive surgery, along with related instruments and accessories. The company operates globally, serving hospitals and surgical centers across multiple continents.
ISRG currently ranks #20 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $150B
- P/E (trailing)
- 41x
- Revenue (TTM)
- $11B
- Net margin
- 28.4%
- EPS (TTM)
- $10.23
- Gross margin
- 67.8%
- Revenue growth (3-yr avg)
- 22.0%
- Shares outstanding
- 353M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 68 · neutral
- 50-day average
- $391.67
- 200-day average
- $439.63
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
- Momentum score
- 87 · grade A
- Positive weeks (of 12)
- 3
Earnings how computed
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+38.6%)
2026-03 ▲ beat (+18.5%)
2025-12 ▲ beat (+11.5%)
2025-09 ▲ beat (+20.6%)
2025-06 ▲ beat (+14.1%)
2025-03 ▲ beat (+4.6%)
2024-12 ▲ beat (+23.5%)
2024-09 ▲ beat (+12.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 24 buy · 7 hold · 1 sell (32 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $479
- Target vs last price
- +13.0%
What our data shows for ISRG
- Our model validated 17 trailing price-to-earnings windows for ISRG, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $332.02–$592.85.
- The 14-day relative strength index sits at a neutral 68.
- 3 of the last 12 weekly snapshots showed positive price momentum.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ISRG
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ISRG news
TickrTrends' derived news-sentiment signal for ISRG is currently leaning positive, computed from recent coverage.
- Intuitive Surgical (ISRG) Shares Dip Despite Strong Q3 Results on Growth Outlook (gurufocus.com, 2026-10-21)
TickrTrends take: Intuitive Surgical's share price decline following strong quarterly performance suggests the market may be pricing in concerns about future growth that extend beyond current operational results. TickrTrends' undervalued assessment indicates the market reaction could present a valuation opportunity, particularly if the company's growth outlook stabilizes or improves from current expectations. For valuation-focused investors in the Healthcare sector, monitoring management guidance and any updates on procedure volume trends will be important to confirm whether the market's caution reflects genuine headwinds or represents temporary pessimism. - ISRG Maintained by JP Morgan -- Price Target Raised to $475 (gurufocus.com, 2026-10-21)
TickrTrends take: JP Morgan's raised price target of 475 dollars for ISRG suggests analyst confidence in the company's prospects within the Healthcare sector. This analyst action provides context for TickrTrends' current Undervalued assessment, indicating that the market may not yet be fully pricing in the potential that some professionals see in the company. Valuation-focused readers should monitor whether ISRG's market price movement toward or away from this target level validates or challenges the current undervaluation premise. - Q3 2026 Intuitive Surgical, Inc. Earnings Call Transcript (gurufocus.com, 2026-10-21)
TickrTrends take: I cannot write this response because no specific financial data from the Q3 2026 earnings call has been provided. To write factual prose for a stock research page, I would need concrete figures such as revenue, earnings per share, operating margins, or other metrics from the transcript. Without these specific facts, any statement comparing ISRG's performance to its Undervalued designation would require me to either invent data or make assumptions, both of which violate your instructions. If you can provide the actual financial metrics from the earnings call, I would be happy to write the requested analysis.
More ISRG news
- Intuitive Surgical (ISRG) Reports Strong Q3 Growth, Undervalued by GF Value™ (gurufocus.com, 2026-10-21)
- Intuitive Surgical (ISRG) Set to Report Q3 Earnings Amid Strong Valuation Signal (gurufocus.com, 2026-10-19)
- Intuitive Surgical Q3 2026 Earnings Preview (NASDAQ:ISRG) (seekingalpha.com, 2026-10-19)
- Intuitive Surgical is Down this Year Despite Double-Digit Growth. Is Its 33x Valuation Still Justified? (insidermonkey.com, 2026-10-16)
- ISRG Maintained by BTIG -- Price Target Lowered to $454 (gurufocus.com, 2026-10-12)
- Intuitive Surgical, Inc. (ISRG) Exceeds Market Returns: Some Facts to Consider (zacks.com, 2026-10-09)
- Intuitive Surgical (ISRG) and JNJ Give Jim Cramer More Than Valuation to Consider (insidermonkey.com, 2026-10-07)
What people are saying
Follow the ISRG conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — ISRG's technical indicators shifted this week as its Relative Strength Index moved from overbought territory into neutral zone, suggesting reduced momentum in price movement. The stock currently carries an undervalued assessment based on TickrTrends' derived indicators within the Healthcare sector.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — ISRG's momentum indicator improved this week, moving from none to A, while the relative strength index shifted from neutral territory into overbought conditions. The stock currently carries an undervalued valuation verdict despite these technical developments. These mixed signals suggest increased upward price movement alongside stretched valuation metrics within the Healthcare sector.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ISRG stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ISRG is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is ISRG's TickrTrends verdict?
ISRG's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does ISRG compare to other Healthcare stocks?
ISRG ranks #20 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ISRG overbought or oversold?
ISRG's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does ISRG usually beat earnings estimates?
Over its last 8 reported quarters ISRG beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ISRG?
Of 32 analysts covering ISRG, 24 rate it a buy, 7 a hold and 1 a sell - buy-leaning, with a consensus price target of $479 (+13.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ISRG vs GEHC · ISRG vs IDXX · ISRG vs INCY · ISRG vs INDV · ISRG vs PGNY